Last updated: July 31, 2026
The exact three-ingredient combination of magnesium hydroxide, omeprazole and sodium bicarbonate does not correspond to a well-established FDA-approved drug, major branded product or clearly defined commercial market. The closest approved product is omeprazole plus sodium bicarbonate, marketed in the United States as Zegerid and generic equivalents. Magnesium hydroxide is widely used as a separate over-the-counter antacid and laxative, but it is not a standard active ingredient in the approved omeprazole/sodium bicarbonate formulation.[1][2]
As a result, the commercial opportunity, clinical-trial pipeline and patent analysis for the exact combination are materially different from those for omeprazole, omeprazole/sodium bicarbonate, or magnesium hydroxide products considered separately.
What drug contains magnesium hydroxide, omeprazole and sodium bicarbonate?
No major FDA-approved product is identified as containing all three ingredients as active components.
| Ingredient |
Pharmacologic role |
Common U.S. status |
Principal use |
| Omeprazole |
Proton-pump inhibitor |
Prescription and OTC |
GERD, erosive esophagitis, peptic ulcer disease, H. pylori regimens |
| Sodium bicarbonate |
Antacid and alkalinizing agent |
OTC and combination products |
Rapid acid neutralization; stabilizes omeprazole in certain formulations |
| Magnesium hydroxide |
Antacid and osmotic laxative |
OTC |
Heartburn, acid indigestion and constipation |
The established fixed-dose product is omeprazole plus sodium bicarbonate. Zegerid capsules and powder for oral suspension contain omeprazole and sodium bicarbonate, not magnesium hydroxide.[1] Magnesium hydroxide may be administered separately as a rescue antacid or laxative, but that use does not create a fixed-combination drug market.
How does the omeprazole and sodium bicarbonate formulation work?
Omeprazole suppresses gastric acid by irreversibly inhibiting the gastric H+/K+-ATPase proton pump. Sodium bicarbonate raises gastric pH and protects omeprazole from acid degradation before absorption. The formulation is designed for immediate-release delivery rather than the delayed-release mechanism used by conventional enteric-coated omeprazole products.[1]
Magnesium hydroxide would provide additional acid-neutralizing capacity, but its inclusion creates formulation and labeling issues:
- Magnesium hydroxide can increase the total antacid load.
- Magnesium exposure creates renal-safety and hypermagnesemia considerations.
- The ingredient has a laxative effect at higher doses.
- A fixed combination would require new stability, bioavailability, dose-ratio and safety work.
- The product would compete with low-cost separate antacids and generic proton-pump inhibitors.
The combination therefore has a pharmacologic rationale but no established regulatory or commercial position comparable to omeprazole/sodium bicarbonate.
What is the FDA regulatory status of the exact triple combination?
The exact triple combination is not an established FDA-approved active-ingredient combination in the principal U.S. prescription-drug databases and labeling sources used for commercial products. FDA-approved omeprazole/sodium bicarbonate products include prescription and OTC formulations, while magnesium hydroxide products are generally regulated separately as OTC antacids or laxatives.[1][3]
A developer seeking approval for the triple combination would likely need to establish:
- Safety and tolerability of the fixed doses.
- Comparative bioavailability against approved omeprazole products.
- Adequate control of gastric-acid-related indications.
- Magnesium exposure in patients with impaired renal function.
- Stability of omeprazole in the presence of both alkalinizing ingredients.
- Appropriate labeling for antacid, GERD and ulcer indications.
The regulatory route would depend on the proposed claims and formulation. A new drug application or an abbreviated new drug application would not automatically be available for a triple product merely because each ingredient is individually marketed.
What clinical trials exist for magnesium hydroxide, omeprazole and sodium bicarbonate?
The clinically established evidence base is concentrated in the individual ingredients and the omeprazole/sodium bicarbonate combination. There is no prominent late-stage clinical program associated with the exact triple formulation.
Omeprazole clinical evidence
Omeprazole has extensive clinical support for:
- Gastroesophageal reflux disease.
- Healing and maintenance of erosive esophagitis.
- Duodenal and gastric ulcers.
- H. pylori eradication regimens.
- Hypersecretory conditions, including Zollinger-Ellison syndrome.
Its clinical development is mature. New trials generally focus on comparative effectiveness, pediatric use, dosing strategies, drug interactions, or treatment sequencing rather than establishing omeprazole as a new active pharmaceutical ingredient.[4]
Omeprazole and sodium bicarbonate trials
Clinical studies of omeprazole/sodium bicarbonate have evaluated immediate-release delivery, nocturnal acid control, GERD symptoms and comparisons with delayed-release proton-pump inhibitors. The formulation’s commercial rationale is rapid absorption and reduced dependence on enteric coating, although clinical differentiation from generic delayed-release omeprazole is limited.[1][5]
Magnesium hydroxide evidence
Magnesium hydroxide is supported primarily by long-standing OTC use and monograph-based regulation. Its established roles are temporary relief of heartburn and treatment of occasional constipation. Modern clinical development is generally unnecessary for those uses unless a sponsor proposes a new indication, delivery system, dose, or fixed combination.[3]
Trial and pipeline assessment
| Development category |
Status |
| Exact triple fixed-dose product |
No established late-stage program identified |
| Omeprazole monotherapy |
Mature, widely studied |
| Omeprazole/sodium bicarbonate |
Approved and commercially available |
| Magnesium hydroxide monotherapy |
Mature OTC product |
| New triple-combination indication |
No established pivotal evidence base |
| Biosimilar development |
Not applicable |
| Generic substitution risk |
High for omeprazole products |
What patents protect omeprazole and sodium bicarbonate products?
The original patents covering omeprazole and major branded formulations have expired or are no longer strong barriers to generic entry. Omeprazole is available from numerous generic manufacturers, and the omeprazole/sodium bicarbonate formulation also faces generic competition.
Patent protection may still arise from:
- Specific dosage forms.
- Powder-for-suspension presentations.
- Sachet or packet packaging.
- Stabilization systems.
- Immediate-release formulations.
- Pediatric dosing systems.
- Manufacturing processes.
- Method-of-use claims.
- Combination products with distinct dose ratios.
These rights are narrower than the original compound patent and generally provide less durable exclusivity. A formulation patent would need to claim a technically distinctive composition or process that is not anticipated by prior omeprazole, bicarbonate and antacid disclosures.
How strong is the patent estate for the exact triple combination?
The patent estate appears weak as a market barrier unless a sponsor has developed a novel formulation or delivery system. The ingredients are old, widely disclosed and inexpensive. A new patent would likely depend on:
- A specific particle-size distribution.
- A novel buffering system.
- Improved omeprazole stability.
- Reduced magnesium-related adverse effects.
- A controlled-release or immediate-release profile.
- A clinically demonstrated advantage over separate administration.
A simple admixture of magnesium hydroxide, omeprazole and sodium bicarbonate would face substantial obviousness and enablement risks under U.S. patent law.
When does omeprazole lose exclusivity?
Omeprazole compound exclusivity has expired in the United States. Generic omeprazole products are widely marketed. The principal commercial protection for branded products now depends on formulation differentiation, brand recognition, distribution and over-the-counter positioning rather than core active-ingredient exclusivity.[1][6]
For omeprazole/sodium bicarbonate products, generic entry has also reduced exclusivity. Any remaining protection is product-specific and may involve formulation, labeling or manufacturing patents listed in FDA databases or asserted in litigation. Patent expiration should be assessed at the individual product level rather than inferred from omeprazole’s original compound history.
What is the Orange Book status of omeprazole and sodium bicarbonate?
The relevant Orange Book analysis applies to approved omeprazole/sodium bicarbonate products, not to the unestablished triple combination. FDA Orange Book listings may identify:
- Reference-listed drugs.
- Approved generic equivalents.
- Patent information submitted by the application holder.
- Pediatric exclusivity or other listed exclusivity.
- Dosage-form and strength distinctions.
The presence of an Orange Book patent does not guarantee a durable commercial barrier. Generic applicants can submit Paragraph IV certifications challenging listed patents, or they may wait for expiration and file under other certification pathways.[6]
Which companies are challenging omeprazole market exclusivity?
The principal competitive pressure comes from generic manufacturers rather than biosimilar developers. Omeprazole is a small-molecule drug, so biosimilar regulation does not apply. Generic competition includes manufacturers selling delayed-release capsules, tablets and, in some cases, omeprazole/sodium bicarbonate formulations.
Competition is strongest in:
- Generic omeprazole delayed-release capsules.
- OTC omeprazole products.
- Lansoprazole, pantoprazole and esomeprazole.
- Famotidine and other H2-receptor antagonists.
- Calcium carbonate and magnesium hydroxide antacids.
- Combination products sold through retail pharmacies and private labels.
No biosimilar risk exists for the exact product because the ingredients are chemically synthesized small molecules.
What generic entry risks exist for a triple-combination product?
Generic entry risk would be high if a triple product reached approval without strong formulation patents. The active ingredients are inexpensive, familiar to regulators and available from multiple suppliers. A generic applicant could potentially challenge:
- The active-ingredient combination.
- The dose ratio.
- The dosage form.
- The manufacturing process.
- The product’s stability profile.
- Method-of-use claims.
The principal defense would be a technically narrow formulation patent supported by comparative pharmacokinetic or clinical data. Market exclusivity based only on combining three known antacid and acid-suppression ingredients would likely be vulnerable.
How does the exact triple combination compare with established therapies?
| Product category |
Acid suppression |
Immediate symptom relief |
Constipation effect |
Commercial position |
| Omeprazole delayed-release |
High, sustained |
Slow relative to antacids |
None |
Large generic market |
| Omeprazole/sodium bicarbonate |
High, potentially faster onset |
Moderate |
None |
Approved niche formulation |
| Magnesium hydroxide alone |
Low to moderate neutralization |
Fast |
Yes |
Low-cost OTC |
| Triple combination |
Potentially high plus rapid neutralization |
Potentially high |
Possible |
Not established |
| Famotidine |
Moderate |
Faster than PPIs |
None |
Mature alternative |
| Calcium carbonate antacid |
Short-duration neutralization |
Fast |
None or variable |
Large OTC category |
The triple product would need a clear benefit over taking a generic PPI plus an inexpensive antacid separately. Possible claims could include faster symptom relief, improved nocturnal acid control or simplified dosing. Each claim would require supporting clinical evidence.
What is the market size and forecast for this drug?
A standalone market forecast for the exact triple combination is not supportable because there is no clearly established approved product, sales base or validated development pipeline. The relevant addressable markets are adjacent categories:
- Global proton-pump inhibitors.
- U.S. OTC heartburn medicines.
- Prescription GERD therapies.
- Magnesium hydroxide antacids and laxatives.
- Immediate-release omeprazole formulations.
These markets are mature and highly price-sensitive. Revenue growth is driven mainly by volume, private-label expansion, retail distribution and shifts between prescription and OTC channels. Generic omeprazole pricing places downward pressure on any new combination product unless it offers measurable clinical or convenience benefits.
Commercial projection scenarios
| Scenario |
Likely commercial result |
| No approved triple product |
No direct product revenue |
| Approval without meaningful differentiation |
Limited niche uptake and rapid price erosion |
| Approval with faster onset or superior symptom control |
Moderate specialty or OTC opportunity |
| Strong formulation patent plus clinical differentiation |
Higher launch value, subject to generic challenge |
| Separate co-administration of generic omeprazole and magnesium hydroxide |
Low-cost substitute that limits pricing power |
A new product would probably compete as a convenience or symptom-relief product rather than as a novel acid-suppression therapy. The strongest commercial opportunity would be an OTC formulation with clear dosing simplicity and a favorable safety profile.
What manufacturing and intellectual-property barriers apply?
Manufacturing barriers are moderate rather than high. Omeprazole is sensitive to acidic conditions, which makes pH control and stability important. Sodium bicarbonate provides an alkaline environment, while magnesium hydroxide changes suspension behavior, particle distribution and dose uniformity.
Key development risks include:
- Chemical stability of omeprazole.
- Uniform dispersion of magnesium hydroxide.
- Sedimentation in liquid products.
- Dose consistency in suspensions.
- Magnesium accumulation in renal impairment.
- Taste and patient acceptability.
- Packaging moisture protection.
- Compatibility with excipients.
- Shelf-life validation.
These issues can support formulation patents but may also increase development cost and manufacturing complexity. They do not create the type of biological manufacturing barrier associated with monoclonal antibodies or other biologics.
What litigation and settlement agreements affect the product?
There is no major publicly established litigation or settlement framework specifically associated with the exact magnesium hydroxide/omeprazole/sodium bicarbonate combination. Litigation exposure would arise if a sponsor obtained approval and listed formulation or method-of-use patents in the Orange Book.
For an approved product, likely disputes would involve:
- Paragraph IV patent challenges.
- Invalidity claims based on obviousness.
- Non-infringement claims based on different excipients or dose ratios.
- Labeling disputes involving method-of-use claims.
- ANDA approval timing.
- Generic launch before patent expiry.
Absent an approved reference product and listed patents, there is no current product-specific Paragraph IV timetable to assess.
Key Takeaways
- The exact magnesium hydroxide/omeprazole/sodium bicarbonate combination is not an established FDA-approved commercial drug.
- The closest approved product is omeprazole plus sodium bicarbonate, including Zegerid and generic equivalents.
- Magnesium hydroxide is generally marketed separately as an OTC antacid and laxative.
- Omeprazole has extensive clinical evidence, but the triple combination lacks a comparable pivotal-trial program.
- Biosimilar risk is irrelevant because all three ingredients are small-molecule products.
- Generic-entry risk would be high for a new triple combination unless it has strong formulation or method-of-use patents.
- A viable product would need to demonstrate a clear advantage over generic omeprazole plus a separate low-cost antacid.
- The adjacent markets are mature, fragmented and subject to significant price competition.
- No reliable standalone revenue projection exists for the exact triple combination without an identified approved product, sponsor and commercial launch.
FAQs
Is magnesium hydroxide compatible with omeprazole?
Potentially, but compatibility depends on the formulation, dose, pH, excipients and storage conditions. A fixed-dose product would require stability and bioavailability testing.
Is sodium bicarbonate necessary in omeprazole products?
No. Conventional omeprazole products use enteric protection. Sodium bicarbonate is used in specific immediate-release formulations to create an alkaline environment and protect omeprazole from degradation.[1]
Can magnesium hydroxide make omeprazole work faster?
Magnesium hydroxide can neutralize existing gastric acid rapidly, but it does not replace omeprazole’s proton-pump inhibition. A faster symptom-relief claim would require clinical testing of the complete formulation.
Are there biosimilars for omeprazole?
No. Omeprazole is a chemically synthesized small molecule. Approved competitors are generics, not biosimilars.
Would a new triple-combination drug receive new-drug exclusivity?
Potentially, depending on the regulatory pathway and the extent of clinical innovation. A new fixed combination would not automatically receive broad exclusivity merely because its ingredients are combined in one product.
References
- U.S. Food and Drug Administration. (2023). Zegerid: Omeprazole and sodium bicarbonate prescribing information.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products database.
- U.S. Food and Drug Administration. (2022). Antacid products containing magnesium hydroxide: Over-the-counter drug monograph framework.
- U.S. Food and Drug Administration. (2022). Omeprazole prescribing information and labeling database.
- ClinicalTrials.gov. (2024). Studies involving omeprazole and omeprazole/sodium bicarbonate formulations. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
